(Q37797337)

23 August 2017

title

What's new in neoadjuvant therapy for breast cancer? (English)

1 reference

23 August 2017

0 references

John A Olson

2

1 reference

23 August 2017

language of work or name

1 reference

1 January 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

44

1 reference

23 August 2017

page(s)

199-228

1 reference

Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Revision of the American Joint Committee on Cancer staging system for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Locally Advanced and Inflammatory Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Prognostic factors in locally advanced noninflammatory breast cancer. Long-term results following primary chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Neoadjuvant chemotherapy in 126 operable breast cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Primary medical (neo-adjuvant) chemotherapy for operable breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Breast conservation after neoadjuvant chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Conservation surgery after primary chemotherapy in large carcinomas of the breast

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Further observations on the inhibition of tumor growth byC. parvum with cyclophosphamide.VII. Effect of treatment prior to primary tumor removal on the growth of distant tumor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Neoadjuvant chemotherapy in operable breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Breast tumour response to primary chemotherapy predicts local and distant control as well as survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Estrogen and progesterone receptor concentrations and prevalence of tumor hormonal phenotypes in older breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Preoperative chemotherapy induces apoptosis in early breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Neo-adjuvant chemotherapy for operable breast cancer induces apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Neoadjuvant endocrine therapy for locally advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Systematic review: gene expression profiling assays in early-stage breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

HER-2 and topoisomerase II as predictors of response to chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

The interaction of oestrogen receptor status and pathological features with adjuvant treatment in relation to survival in patients with operable breast cancer: a retrospective study of 2660 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Neoadjuvant use of endocrine therapy in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly Breast Cancer Working Party

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Cardiotoxicity concerns prompt data review in breast cancer trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Accuracy of MRI in the Detection of Residual Breast Cancer After Neoadjuvant Chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with x-ray mammography and palpation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

7 January 2021

PET/CT and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Changes in Glucose Metabolism and Blood Flow Following Chemotherapy for Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

A Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Management and survival of female breast cancer: results of a national survey by the American College of Surgeons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Meta-analysis of sentinel lymph node biopsy in breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy for Advanced Breast Cancer: Results of Ganglion Sentinelle et Chimiothérapie Neoadjuvante, a French Prospective Multicentric Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Sentinel lymph node biopsy after neoadjuvant systemic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Timing of sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Predictive markers of response to neoadjuvant chemotherapy in breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Molecular portraits of human breast tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2010.05.013

10.1016/J.YASU.2010.05.013

7 January 2021

Identifiers

DOI

1 reference

23 August 2017

1 reference